TREVI THERAPEUTICS INC's ticker is TRVI and the CUSIP is 89532M101. A total of 24 filers reported holding TREVI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $406,529 | -8.8% | 186,481 | 0.0% | 0.01% | -9.1% |
Q2 2023 | $445,690 | +27.9% | 186,481 | -1.0% | 0.01% | +22.2% |
Q1 2023 | $348,540 | -13.3% | 188,400 | -9.6% | 0.01% | -10.0% |
Q4 2022 | $402,212 | +64.2% | 208,400 | +30.8% | 0.01% | +42.9% |
Q3 2022 | $245,000 | -14.9% | 159,300 | +55.3% | 0.01% | 0.0% |
Q2 2022 | $288,000 | +74.5% | 102,600 | +36.8% | 0.01% | +133.3% |
Q1 2022 | $165,000 | +179.7% | 75,000 | 0.0% | 0.00% | +200.0% |
Q4 2021 | $59,000 | +25.5% | 75,000 | +116.8% | 0.00% | 0.0% |
Q3 2021 | $47,000 | -39.7% | 34,600 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $78,000 | -73.9% | 34,600 | -68.4% | 0.00% | -83.3% |
Q1 2021 | $299,000 | +23.6% | 109,600 | +9.6% | 0.01% | +20.0% |
Q4 2020 | $242,000 | -40.0% | 100,000 | 0.0% | 0.01% | -44.4% |
Q3 2020 | $403,000 | -38.8% | 100,000 | 0.0% | 0.01% | -30.8% |
Q2 2020 | $658,000 | +166.4% | 100,000 | +33.3% | 0.01% | +116.7% |
Q1 2020 | $247,000 | -12.1% | 75,000 | 0.0% | 0.01% | +50.0% |
Q4 2019 | $281,000 | – | 75,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NEA Management Company, LLC | 11,370,376 | $24,787,420 | 1.91% |
Fairmount Funds Management LLC | 5,163,287 | $11,255,966 | 1.35% |
Opaleye Management Inc. | 1,705,900 | $3,718,862 | 1.21% |
Frazier Life Sciences Management, L.P. | 6,881,090 | $15,000,776 | 1.00% |
VR Adviser, LLC | 3,422,397 | $7,460,825 | 0.78% |
SILVERARC CAPITAL MANAGEMENT, LLC | 927,415 | $2,021,765 | 0.61% |
Rubric Capital Management LP | 5,684,420 | $12,392,036 | 0.46% |
Tejara Capital Ltd | 180,227 | $392,895 | 0.22% |
PFS Partners, LLC | 100,000 | $218,000 | 0.19% |
WealthTrust Axiom LLC | 93,500 | $203,830 | 0.07% |